Ticagrelor's Adenosine-Mediated Effect and the Accuracy of Fractional Flow Reserve  by Palmer, Sonny et al.
Correspondence JACC Vol. 62, No. 7, 2013
August 13, 2013:644–8
646*Heinrich Taegtmeyer, MD, DPhil
*University of Texas Medical School at Houston





1. Lüderitz B, Holmes DR, Harold J. The history of the German Cardiac
Society and the American College of Cardiology and their two founders.
J Am Coll Cardiol 2013;61:802–7.
2. Palmier JM. Weimar in Exile: The Anti-Fascist Emigration in Europe
and America (translated by David Fernbach). New York: Verso, 2006.
3. Medawar J, Pyke D. Hitler’s Gift: The True Story of Scientists Expelled
by the Nazi Regime. New York, NY: Arcade, 2000.
4. Paul O. Take Heart: The Life and Prescription for Living of Dr. Paul
Dudley White. Boston, MA: Harvard University Press, 1986.ReplyI would like to thank Dr. Taegtmeyer very much indeed for his
ﬁne letter concerning our recent publication in the Journal (1).
I appreciate very much his comments and his personal experiences
in the twilight of the darkest period of Germany’s history. I am
chairman of the Task Force on History of Cardiology in
Germany; we are preparing a comprehensive report on the
political involvement of German and Austrian cardiologists
during the so-called Third Reich. I would be glad to inform
Dr. Taegtmeyer about our ongoing efforts nearer the time of
publication.
Once again, I thank Dr. Taegtmeyer for his interest in our work.
*Berndt Lüderitz, MD, PhD, MD (Hon)
*University of Bonn
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Effect and the Accuracy of
Fractional Flow Reserve
We read with great interest the paper by Wittfeldt et al. (1), which
demonstrated that the novel adenosine diphosphate receptor
P2Y12 antagonist, ticagrelor, augments the adenosine-inducedincrease in coronary blood ﬂow velocity in healthy volunteers.
Ticagrelor has been shown to improve clinical outcomes in patients
with acute coronary syndromes compared with clopidogrel (2), and
its use is now recommended as ﬁrst-line therapy by international
guidelines (3,4).
The ﬁndings of this study may have important clinical impli-
cations in those patients who are taking ticagrelor and subsequently
require measurement of fractional ﬂow reserve (FFR) to assess the
hemodynamic signiﬁcance of coronary lesions. Accurate FFR
measurement requires maximal coronary hyperemia, and it is
recommended that this should be achieved with a continuous
intravenous infusion of adenosine at a rate of 140 mg/kg/min (5).
Although most studies have been performed using a maximum
infusion rate of 140 mg/kg/min, this may not achieve maximal
hyperemia in some patients. It has been suggested that higher doses
may be required to obtain accurate results (6).
Because ticagrelor has been shown to enhance adenosine-
induced vasodilatation, the degree of hyperemia obtained with
adenosine infusion may be greater than that obtained in patients
taking clopidogrel. This would lead to a lower FFR and a more
accurate reﬂection of the true functional signiﬁcance of a coronary
lesion.
The increasing use of ticagrelor in the future may also allow for the
routine use of intracoronary adenosine, because it has previously
been shown to be less reliable and more problematic than intrave-
nous infusion (6). If this is the case, the adoption of this more
simpliﬁed method may translate into an increased utilization of FFR
as a valuable investigative procedure with subsequent improved
patient outcomes and cost-effectiveness.*Sonny Palmer, BA, BSc, MBBS
Andrew Wilson, MBBS, PhD
Christopher Judkins, MBBS
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Cardiol Int 2011;4:1093–5.ReplyWe thank Dr. Palmer and colleagues for commenting on 1 of the
potential important implications of our recently reported ﬁnding
(1). We demonstrated, in healthy volunteers, that ticagrelor
enhanced coronary vasodilatory response to adenosine through
increased sensitivity to adenosine, as shown by a greater area under
the curve for adenosine dose versus coronary blood ﬂow when
ticagrelor was used. A maximum signiﬁcant additive effect was seen
at a submaximal adenosine dose of 80 mg/kg/min. The study was
conducted in healthy volunteers to avoid any confounders, such as
concomitant medications, etc.
Adenosine is a widely used cardiac stress agent for measurement
(e.g., fractional ﬂow reserve [FFR]). However, it has been shown
that maximum hyperemia could not be achieved in all patients
using the standard intravenous adenosine dose of 140 kg/min (2).
Interestingly, the variability in adenosine response could also be
partially explained by the genetic polymorphism in adenosine
receptors (3).
In patients with various risk factors, impaired coronary ﬂow
velocity reserve (CFVR) has been reported and has also shown
strong predictive values for future cardiovascular outcomes (4).
Thus, it is conceivable that ticagrelor may also enhance the
maximum hyperemic response in patients with impaired CFVR
through increased hyperemic ﬂow velocity response. If that is the
case, this will lead to an increased drop in pressure over a certain
stenosis, and thereby, lower the FFR value. As correctly pointed out
by Palmer et al., this will likely improve the accuracy and consis-
tency of FFR measurements in the future.
Finally, because our data were generated in healthy volunteers,
the concept still needs to be demonstrated in patients with coronary
artery disease. Thus, more studies are warranted to prove the
hypothesis raised by Palmer et al.*Li-Ming Gan, MD, PhD
Ann Wittfeldt, MD
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Cardiol Img 2012;5:1079–85.Choosing Troponin Immunoassays
in a World of Limited Resources
We read with interest the report by Korley and Jaffe (1), who
elaborated several critical issues as a means of educating clinicians
about cardiac troponin immunoassays. Although the investigators
should be praised for their effort to synthesize and emphasize the
leading problems and drawbacks, another important issue engages
the minds of clinicians and laboratory professionals. There is open
debate about the different analytical and clinical performance of the
different troponin immunoassays (2,3). Because of the ongoing
economic crisis and the increasing pressure placed on clinical
laboratories to conserve economic and human resources, there is
a widespread phenomenon of merging of existing clinical labora-
tories into larger ones, accompanied by consolidation of different
tests within multitasking analytical platforms (4). The in vitro
diagnostic industry is continuously developing and marketing
integrated instrumentation, where the consolidation of most clin-
ical chemistry and a variety of immunochemistry tests is indeed an
efﬁcient and cost-effective solution in a world of limited resources.
What some clinicians often ignore is that the procedures for
purchasing instrumentations and reagents in clinical laboratories
are challenging and increasingly involve a large number of tests
rather than individual parameters (4). Regardless of its unques-
tionable clinical value for cardiologists and emergency physicians,
troponin testing is only a minor part of the game in the context of
a large tender for laboratory equipment, so that the acquisition of
dedicated instrumentation to measure only troponin is becoming
problematic, especially in some European countries. In this
perspective, the question as to whether troponin T may be better
than troponin I for identifying myocardial injury, and even whether
one troponin I immunoassay may perform better than another for
diagnosing myocardial infarction, will become virtually academic in
the foreseeable future, provided that the methods are straightfor-
ward and fulﬁll basic criteria of analytical quality (5).
All that said, a reasonable solution can be developed. Supported by
science, rather than the market, the in vitro diagnostic companies
should be encouraged to reach a formal agreement to standardize
their immunoassays around 1 molecule (either cardiac troponin I or
T) and, even more important, on immunoassays calibrated using an
identical reference material and containing a cocktail of antibodies
that recognize the same andmore analytically suitable epitopes of the
proteins. This solution would also be more effective than continuing
to pursue a challenging harmonization or an unlikely standardization
of the different troponin I methods (6).*Giuseppe Lippi, MD
Gianfranco Cervellin, MD
